![]() During REGAIN, changes in concomitant MG therapies were not permitted during the OLE, they were permitted at the investigators' discretion. Eligible patients had received ≥2 ISTs for ≥1 year or ≥1 IST with intravenous immunoglobulin or plasma exchange ≥4 times in 1 year, without symptom control. Methods: The REGAIN open-label extension (OLE) enrolled 117 adults with refractory anti-acetylcholine receptor antibody-positive gMG who had completed the 6-month, randomized, double-blind, placebo-controlled REGAIN study of eculizumab. We therefore examined IST use in eculizumab-treated patients with refractory gMG. Introduction: Chronic, broad-spectrum immunosuppressive therapy (IST) can be associated with side effects in many people with generalized myasthenia gravis (gMG), and treatment guidelines recommend that the IST dose be tapered once patients achieve a stable treatment response. 5Department of Neurology, University of North Carolina, Chapel Hill, NC, United States.4Alexion Pharmaceuticals, Boston, MA, United States.3Department of Neurology, University of Southern California, Los Angeles, CA, United States.2Department of Neurology and Neurosciences, Stanford University School of Medicine, Stanford, CA, United States.1Department of Neurology, Yale University School of Medicine, New Haven, CT, United States.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |